ArticleFrontiers in medicine2026
Incremental value of the perivascular fat attenuation index surrounding the superior mesenteric artery on non-contrast CT for predicting SMA abnormalities in patients with acute abdominal pain.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the predictive value of the perivascular fat attenuation index (FAI) surrounding the superior mesenteric artery (SMA) on non-contrast CT for SMA abnormalities in acute abdominal pain and FAI's incremental utility in risk models. Methods: This retrospective study included 262 acute abdominal pain patients (77 with SMA abnormalities, 185 controls) admitted between January 2020 and December 2025. All underwent non-contrast and contrast-enhanced CT within 48 h. Independent predictors were identified via univariate and multivariate logistic regression. The maximum area under the curve (AUC) was obtained through receiver operating characteristic analysis, and the predictive performance of models was comprehensively evaluated using net reclassification (NRI) and integrated discrimination improvement (IDI). Decision curve analyses (DCA) and calibration curves were used to evaluate the clinical utility and calibration of the models. Results: Independent predictors of SMA abnormalities were smoking (OR = 10.452, 95% CI: 2.528-43.219), elevated high-sensitivity C-reactive protein [hsCRP] (OR = 1.012, 95% CI: 1.001-1.023), increased SMA diameter [SMA-d] (OR = 4.414, 95% CI: 2.758-7.062), and high FAI (OR = 1.092, 95% CI: 1.053-1.132; all Conclusion: A high FAI was independently associated with SMA abnormalities, although its incremental predictive value was lower than that of SMA-d. Thus, FAI might serve as a complementary imaging biomarker rather than a stand-alone diagnostic marker. Integrating smoking status, hsCRP, SMA-d, and FAI might improve early risk stratification based on non-contrast CT and support timely diagnostic evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.